Compare Eli Lilly And Co (LLY) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs LyondellBasell Industries NV — how do they compare? Eli Lilly And Co trades at $1,223 (market cap $1.09T), while LyondellBasell Industries NV trades at $62.4 (market cap $20.29B). The key difference: Eli Lilly And Co is far larger — about 53.7× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (6.56%). Which is the better fit depends on your goals.
| LLY | LYB | |
|---|---|---|
Market Cap | $1.09T | $20.29B |
Sector | Health | Basic Materials |
52-Week High | $1.24K | $82.38 |
52-Week Low | $660.49 | $42.28 |
Enterprise Value | $1.13T | $31.88B |
Dividend Yield | 0.57% | 6.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
LyondellBasell Industries (LYB) trades at $62.79, up 0.22% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $4.30 versus $3.44 estimated, driven by improved margins from supply disruptions. However, 2025 fundamentals show challenges, including a net loss of $745 million and negative profit margins, though cash flow from operations remains positive at $2.26 billion.
The stock offers potential upside to the $70.56 analyst consensus target, with 46% of analysts rating it a buy, but faces risks from volatile chemical markets and high debt. Investor sentiment is mixed amid earnings recovery signs and macroeconomic pressures on demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
